NASDAQ Global Market • Healthcare • Biotechnology • US • USD
I-Mab (IMAB) has a consensus analyst rating of Buy, based on 5 analysts covering the stock. Of those, 5 recommend buying, 0 recommend holding, and 0 recommend selling.
No price target data available.
Be the first to know when stocks drop below their intrinsic value.
